The Human Variable 

VitalGuard™ is CYNAERA’s flagship environmental risk engine for infection-associated chronic conditions (IACCs) such as Long COVID, ME/CFS, POTS, MCAS, and Chronic Lyme. It transforms real-time atmospheric and environmental inputs into predictive flare scores that can inform FEMA incident operations, NIH-funded clinical trials, and CDC-aligned public health programs.

The CYNAERA ESA (Emergency Stabilization Authorization) framework presents a solution. During a declared emergency, ESA enables states and FEMA to pre-authorize qualified clinics to operate as temporary micro-ERs and reimburse those services as emergency protective measures. Critically, ESA does not require new legislation. It strategically aligns existing authorities under the Stafford Act for federal disaster declarations, FEMA Public Assistance Category B for emergency pro

Using a multi-model estimation approach, we project that 8–12 million Americans may be experiencing chronic health impacts following vaccination, with 40–50 percent facing functional disability. The associated annual economic burden ranges from $100 to $500 billion. We propose that the adoption of immune-informed readiness protocols could prevent up to 1.6 million cases annually, saving $20–40 billion per year.

The CYNAERA ME/CFS Individualized Regimen Engine™ is an educational modeling framework that simulates phased strategies for ME/CFS care. Built on CYNAERA’s ecosystem of validated modules — including Treatment Archetypes, Phenotyping Framework, Pathophysiology Drivers, and the Path of Remission Model — the Regimen Engine demonstrates how individualized patient care can be systematically structured.

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is profoundly sensitive to environmental stressors. Pollutants such as polycyclic aromatic hydrocarbons (PAHs), particulate matter (PM₂.₅, PM₁₀), nitrogen dioxide (NO₂), ground-level ozone (O₃), sulfur dioxide (SO₂), and volatile organic compounds (VOCs), combined with weather triggers like heat, cold, barometric pressure swings, mold, humidity, and pollen, drive flares that push patients into cycles of severe disabi

CYNAERA has the first clinical intelligence system designed to simulate and stratify patient response across the full complexity of infection-associated chronic conditions (IACCs) such as ME/CFS, Long COVID, POTS, MCAS, EDS, Lyme, CRPS, and related syndromes. Unlike traditional models that flatten patients into crude categories, CYNAERA builds individualized profiles across 11 stratification axes and integrates them with six mechanistic phenotyping domains.

CYNAERA’s AI simulations analyze 120+ therapeutic candidates across 6 mechanisms, weighting them by patient endotype, Pathos™ severity score, and predicted remission probability. This map provides the first public-facing mechanism reference, while full dosing logic, contraindication overlays, and trial-ready protocols remain licensed.

The CDF-Peds-ME/CFS™, developed by CYNAERA, is the first child-adapted Composite Diagnostic Fingerprint designed for school, home, and clinical settings. Built on CYNAERA’s validated CDF-ME framework, it integrates multi-system biomarkers, digital phenotyping, and school-based records into a practical, developmentally appropriate diagnostic solution.

CYNAERA’s PHAROS™ + REWIRE™ framework introduces a longitudinal, multi-pathway diagnostic system. By tracking cytokine rhythms over days, mapping vagal-histaminergic amplification, and integrating viral reactivation profiles, PHAROS™ + REWIRE™ replaces linear models with terrain-aware detection. This paper expands on the biological foundations of this model, critiques failed legacy approaches, and outlines a replicable path to mechanism-specific, real-world diagnostics.

ME/CFS is a relapsing, multisystem condition characterized by immune disruption, neuroinflammation, autonomic dysfunction, and energy metabolism abnormalities. Trials should anchor in stabilization before pursuing cure.

Clinician Guide For MECFS Therapeutics: Built from CYNAERA Diagnostic Fingerprints™ + IACCI Terrain Logic + XR/CR Pharmacology Doctrine

For decades, ME/CFS has been treated as a monolith in research, despite overwhelming evidence of heterogeneity across patients. This failure to stratify has been a primary driver of trial collapse, clinical mismanagement, and neglect. The CYNAERA 25+ ME/CFS Phenotyping List integrates biological, environmental, and social terrain factors into a structured classification system.